6HD4 image
Entry Detail
PDB ID:
6HD4
Keywords:
Title:
ABL1 IN COMPLEX WITH COMPOUND 7 AND IMATINIB (STI-571)
Biological Source:
PDB Version:
Deposition Date:
2018-08-17
Release Date:
2018-10-24
Method Details:
Experimental Method:
Resolution:
2.03 Å
R-Value Free:
0.22
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Tyrosine-protein kinase ABL1
Chain IDs:A, B
Chain Length:293
Number of Molecules:2
Biological Source:Mus musculus
Primary Citation
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
J. Med. Chem. 61 8120 8135 (2018)
PMID: 30137981 DOI: 10.1021/acs.jmedchem.8b01040

Abstact

Chronic myelogenous leukemia (CML) arises from the constitutive activity of the BCR-ABL1 oncoprotein. Tyrosine kinase inhibitors (TKIs) that target the ATP-binding site have transformed CML into a chronic manageable disease. However, some patients develop drug resistance due to ATP-site mutations impeding drug binding. We describe the discovery of asciminib (ABL001), the first allosteric BCR-ABL1 inhibitor to reach the clinic. Asciminib binds to the myristate pocket of BCR-ABL1 and maintains activity against TKI-resistant ATP-site mutations. Although resistance can emerge due to myristate-site mutations, these are sensitive to ATP-competitive inhibitors so that combinations of asciminib with ATP-competitive TKIs suppress the emergence of resistance. Fragment-based screening using NMR and X-ray yielded ligands for the myristate pocket. An NMR-based conformational assay guided the transformation of these inactive ligands into ABL1 inhibitors. Further structure-based optimization for potency, physicochemical, pharmacokinetic, and drug-like properties, culminated in asciminib, which is currently undergoing clinical studies in CML patients.

Legend

Protein

Chemical

Disease

Primary Citation of related structures